Latira (Timolol Maleate, Latanoprost)

Latira combines a beta‑blocker and a prostaglandin analog to manage conditions characterized by elevated intra‑ocular pressure.

• Open‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage.
• Ocular hypertension: lowers eye pressure to prevent progression to glaucoma.
• Post‑surgical intra‑ocular pressure control: helps maintain target pressure after ocular surgery.

• Timolol maleate non‑selectively blocks β‑adrenergic receptors in the ciliary body, decreasing aqueous humor production. Latanoprost, a prostaglandin F2α analogue, binds to FP receptors, remodeling the extracellular matrix and enhancing uveoscleral outflow of aqueous humor. The combined actions result in a net reduction of intra‑ocular pressure, addressing the primary pathogenic factor in glaucoma and ocular hypertension. This dual mechanism provides complementary pressure‑lowering effects throughout the 24‑hour cycle.

Like all ophthalmic medications, Latira may cause local and systemic adverse reactions.

Common Side Effects

• Blurred vision
• Eye irritation or burning sensation
• Redness of the conjunctiva
• Dry eye or foreign body sensation

Serious or Rare Side Effects

• Severe allergic reaction (e.g., eyelid swelling, rash)
• Paradoxical increase in intra‑ocular pressure
• Corneal ulcer or keratitis
• Systemic beta‑blocker effects such as bradycardia or bronchospasm

Before prescribing Latira, clinicians should consider several safety factors.

• Cardiovascular assessment: evaluate heart rate and blood pressure before initiating therapy.
• Respiratory caution: avoid use in patients with severe asthma or chronic obstructive pulmonary disease.
• Concomitant beta‑blockers: monitor for additive systemic beta‑blockade.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation.
• Contact lens wear: remove lenses before instillation and wait before reinserting.
• Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Latira may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Systemic non‑selective beta‑blockers (e.g., propranolol): may cause excessive bradycardia or hypotension.
• Topical adrenergic agonists (e.g., epinephrine): can diminish timolol’s intra‑ocular pressure‑lowering effect.
• Other prostaglandin analog eye drops: increase risk of ocular inflammation.

Moderate Interactions (Monitor Closely)

• Carbonic anhydrase inhibitor eye drops (e.g., dorzolamide): additive IOP reduction may require monitoring.
• Anticholinergic ophthalmic agents: may affect pupil size and comfort.
• Systemic antihypertensive drugs: monitor for enhanced hypotensive response.